After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
PF-08046037 joins PF-08046054 in clinical development.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
